Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Coley Pharmaceutical Group, Inc. (COLY) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/13/2008 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2008 SC 13G/A ZIFF ASSET MANAGEMENT LP reports a 0% stake in Coley Pharmaceutical Group, Inc.
02/06/2008 SC 13G/A FRANKLIN RESOURCES INC reports a 0% stake in Coley Pharmaceutical Group, Inc.
01/04/2008 8-K Quarterly results
01/04/2008 SC 13D PFIZER INC has filed a Schedule 13D for Coley Pharmaceutical Group, Inc.
01/03/2008 SC 13D/A GAMCO INVESTORS, INC. ET AL reports a 0% stake in Coley Pharmaceutical Group, Inc.
12/21/2007 SC 13D GAMCO INVESTORS, INC. ET AL reports a 3.8% stake in Coley Pharmaceutical Group, Inc.
11/20/2007 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer Inc., Corvette Acquisition Corp., and Coley Pharmaceutical Group, Inc"
11/19/2007 SC 13G/A Xmark Opportunity Partners, LLC reports a 0% stake in COLEY PHARMACEUTICAL GROUP, INC.
11/16/2007 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer, Coley Acquisition Corp., and Coley Pharmaceutical Group, Inc",
"Amendment No. 1, to the Stockholder Rights Agreement, between Coley and Computershare Trust Company, N.A",
"PFIZER TO ACQUIRE COLEY PHARMACEUTICAL GROUP - - -",
"Letter to Employees of Coley"
11/02/2007 10-Q Quarterly Report for the period ended September 30, 2007
11/01/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter and Nine-month Financial Results"
10/09/2007 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Stockholder Rights Agreement between the Company and Computershare Trust Company, N.A., which includes as Exhibit A, the Summary of Rights to Purchase Common Stock and as Exhibit B, the Form of Rights Certificate",
"Coley Pharmaceutical Group Adopts Shareholder Rights Plan Wellesley, MA, October 8, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, announced today that its Board of Directors has adopted a Stockholder Rights Plan that is designed to strengthen the ability of the Board of Directors to protect Coley's stockholders. The plan was not adopted in response to any unsolicited offer or takeover attempt. Each stockholder of record of the Company on October 15, 2007, will receive a dividend of one Right for each outstanding share of Common Stock held. Each Right represents the right to purchase, under certain circumstances, one one-hundredth of a share of a new series of preferred stock of t..."
08/08/2007 10-Q Quarterly Report for the period ended June 30, 2007
08/02/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Second Quarter and Six-month Financial Results Wellesley, MA, August 2, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the second quarter and six months ended June 30, 2007. FINANCIAL UPDATES"
07/20/2007 SC 13G Xmark Opportunity Partners, LLC reports a 5% stake in COLEY PHARMACEUTICAL GROUP, INC.
06/29/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV™"
06/22/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer"
06/15/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Amended and Restated 2005 Stock Plan"
06/11/2007 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Coley Pharmaceutical Group Broadens Leading Toll-like Receptor Platform Through Strategic Acquisition of 3M Company's TLR Therapeutic Research and Development Programs"
05/09/2007 10-Q Quarterly Report for the period ended March 31, 2007
05/03/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports First Quarter Financial Results Wellesley, MA, May 3, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the first quarter of 2007. FINANCIAL UPDATES"
04/25/2007 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Licenses VaxImmune™ to Merck for Use in Vaccine Programs"
03/09/2007 10-K Annual Report for the period ended December 31, 2006
02/15/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2006 Financial Results Wellesley, MA, February 15, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the fourth quarter and year ended December 31, 2006. The company also announced its annual corporate objectives and provided full-year 2007 financial guidance."
02/14/2007 SC 13G/A TVM III Limited Partnership reports a 12.1% stake in Coley Pharmaceutical Group, Inc.
02/12/2007 SC 13G/A ZIFF ASSET MANAGEMENT LP reports a 9% stake in Coley Pharmaceutical Group, Inc.
02/05/2007 SC 13G/A FRANKLIN RESOURCES INC reports a 5.2% stake in Coley Pharmaceutical Group, Inc.
01/22/2007 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Financial Statements and Exh...
Docs: "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy"
12/26/2006 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
12/12/2006 8-K Entry into a Material Definitive Agreement
12/08/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Amends Strategic Alliance License Agreement with GlaxoSmithKline for VaxImmune™ Vaccine Adjuvant"
11/08/2006 10-Q Quarterly Report for the period ended September 30, 2006
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy